Literature DB >> 10462067

The neurobiology of cannabinoid analgesia.

J M Walker1, A G Hohmann, W J Martin, N M Strangman, S M Huang, K Tsou.   

Abstract

The discovery of cannabinoid receptors and their putative endogenous ligands raises questions as to the nature of the effects produced by cannabinoids on neural circuits that mediate pain and whether endogenous cannabinoids produced by the brain or in the periphery serve naturally to modulate pain. A sizable body of previous work showed that cannabinoid agonists suppress pain behavior in a variety of models of acute and chronic pain. However, at appropriate doses, cannabinoids also profoundly suppress motor behavior (see Sañudo-Peña et al., this volume), which complicates the interpretation of behavioral analgesia since a motor response is the endpoint of virtually all such studies. Studies conducted in this laboratory used biochemical and neurophysiological measures to determine whether cannabinoids suppress nociceptive neurotransmission. The results showed that cannabinoids suppress nociceptive neurotransmission at the level of the spinal cord and the thalamus. These effects are reversible, receptor mediated, selective for painful as opposed to nonpainful somatic stimuli, and track the behavioral analgesia both in time course and potency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462067     DOI: 10.1016/s0024-3205(99)00289-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  34 in total

Review 1.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

2.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

3.  Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints.

Authors:  S D Gauldie; D S McQueen; R Pertwee; I P Chessell
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

4.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16

Review 6.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 7.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

8.  Distribution of endogenous farnesyl pyrophosphate and four species of lysophosphatidic acid in rodent brain.

Authors:  Sung Ha Lee; Siham Raboune; J Michael Walker; Heather B Bradshaw
Journal:  Int J Mol Sci       Date:  2010-10-15       Impact factor: 5.923

9.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

10.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.